ALiA BioTech Holdings Limited
Developer of a point-of-care, microfluidic lab-on-chip diagnostic platform and single-use biochips for rapid, multiplexed infectious-disease testing. Combines protein microarray and fluorescent immunoassay detection with integrated optical sensing and automated sample-to-answer workflows for clinical and decentralized testing. Operates product development, clinical validation and device production activities and holds multiple intellectual property assets.
Industries
Nr. of Employees
medium (51-250)
ALiA BioTech Holdings Limited
Unit 2, 5/F, Wah Lai Industrial Centre, 10–14 Kwei Tei Street, Fo Tan, Hong Kong
Products
Point-of-care microfluidic diagnostic platform (portable analyzer + single-use biochips)
An integrated POC testing system combining a portable analyzer with optical sensing and single-use microfluidic biochips embedded with protein microarrays to generate multiple diagnostic results from a single small sample.
Rapid COVID-19 antigen test (consumer format)
A rapid antigen test for SARS-CoV-2 that uses immunofluorescent detection to provide a qualitative result from nasopharyngeal swabs or recommended sample types in minutes.
Point-of-care microfluidic diagnostic platform (portable analyzer + single-use biochips)
An integrated POC testing system combining a portable analyzer with optical sensing and single-use microfluidic biochips embedded with protein microarrays to generate multiple diagnostic results from a single small sample.
Rapid COVID-19 antigen test (consumer format)
A rapid antigen test for SARS-CoV-2 that uses immunofluorescent detection to provide a qualitative result from nasopharyngeal swabs or recommended sample types in minutes.
Services
Provision of a portable, automated sample-to-answer analyzer and compatible single-use biochips for decentralized clinical testing.
Design and manufacture of array-based disposable biochips and custom multiplex panels for respiratory, arboviral, STI, sepsis and gastrointestinal infection testing.
A consumer-facing rapid antigen test intended to provide a qualitative result in minutes for detection of viral antigens.
Provision of a portable, automated sample-to-answer analyzer and compatible single-use biochips for decentralized clinical testing.
Design and manufacture of array-based disposable biochips and custom multiplex panels for respiratory, arboviral, STI, sepsis and gastrointestinal infection testing.
A consumer-facing rapid antigen test intended to provide a qualitative result in minutes for detection of viral antigens.
Expertise Areas
- Point-of-care testing (POCT) platform development
- Multiplex infectious-disease diagnostics
- Microfluidic lab-on-chip engineering
- Protein microarray assay development
Key Technologies
- Microfluidics
- Lab-on-chip (LOC)
- Protein microarray
- Fluorescent immunoassay (FIA)
News & Updates
Exhibition of the point-of-care testing platform at AACC Clinical Expo 2023.
Announcement of participation and showcase at AACC Clinical Expo 2023.
Presentation of the point-of-care testing platform at MEDICA 2022.
Clinical study with a university partner evaluating the SARS-CoV-2 antigen fluorescent immunoassay test.
Certified as an ISO 13485:2016 medical device manufacturer since 2018.
Reported CE accreditation for the point-of-care diagnostic platform and related products.
Exhibition of the point-of-care testing platform at AACC Clinical Expo 2023.
Announcement of participation and showcase at AACC Clinical Expo 2023.
Presentation of the point-of-care testing platform at MEDICA 2022.
Clinical study with a university partner evaluating the SARS-CoV-2 antigen fluorescent immunoassay test.
Certified as an ISO 13485:2016 medical device manufacturer since 2018.
Reported CE accreditation for the point-of-care diagnostic platform and related products.